Assessment of Primary Malignancy Risk after Initiation of Biologic Therapy in Patients with Psoriasis.

JID Innov · 2025 · PMC12335983 · PMID 40800120

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Similarly, a lower incidence of any malignancy was observed among patients on IL-23 inhibitors (HR = 0.83; 95% CI = 0.68–1.02), IL-12/23 inhibitors (HR = 0.85; 95% CI = 0.71–1.03), or IL-17 inhibitors (HR = 0.87; 95% CI = 0.73–1.04); however, the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.